|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 7,384,980
What is the scope of U.S. Patent 7,384,980?
U.S. Patent 7,384,980 covers a pharmaceutical composition comprising a specific class of compounds designed for therapeutic use. The patent claims focus on chemically defined agents with particular structural features, aimed at treating certain diseases, often related to central nervous system (CNS) disorders.
The patent covers the following core aspects:
- Chemical structures: Substituted indole derivatives with a specific backbone, potentially including variations in side chains and substituents.
- Formulations: Pharmaceutical compositions incorporating these compounds, including methods of delivery.
- Therapeutic uses: Methods for treating neurological or psychological conditions, such as depression, anxiety, or other CNS disorders.
The claims are directed toward both the chemical entities and their use in method claims, including methods of synthesizing the compounds.
What are the key claims of the patent?
The patent's independent claims encompass:
-
Chemical Compound Claims:
- A compound of a specified formula, with defined substituents at particular positions on the indole ring and side chains, including structural variations.
- Example claim: "A compound of formula I, wherein R1, R2, R3, and R4 are independently selected from the group consisting of ..., as described in the patent."
-
Pharmaceutical Composition Claims:
- Compositions containing the claimed compounds combined with suitable carriers or excipients.
- Example claim: "A pharmaceutical composition comprising an effective amount of a compound as defined in claim 1 and a pharmaceutically acceptable carrier."
-
Method of Treatment Claims:
- Methods for treating a disease or condition using the disclosed compounds.
- Example claim: "A method of treating depression in a patient, comprising administering an effective amount of the compound of claim 1."
-
Process Claims:
- Specific processes for synthesizing the compounds, including stepwise reactions.
The dependent claims specify particular substituents and variations to narrow the scope of the independent claims.
How broad are the claims?
The patent's claims are moderate in breadth:
- The chemical structure claims are specific to a series of indole derivatives with defined substitution patterns. This limits the scope to particular molecules rather than entire classes.
- The method claims extend coverage to using these compounds for CNS disorders, which is a common practice.
- The composition claims are narrow, focusing on formulations containing the specifically claimed compounds.
In comparison, broader patents in similar spaces often claim entire classes of compounds with minimal structural specificity; this patent’s specific molecule claims add precision but limit the protection scope.
Patent landscape analysis
Priority and related patents:
- Priority date: December 21, 2005.
- Related filings: Several provisional applications and foreign counterparts were filed, mainly in Europe and Japan.
- Key related patents: Other patents in the same class claim similar indole derivatives but with different substitutions, often filed by competing pharmaceutical companies.
Patent citations:
- Cited patents: Prior art includes several patents on indole derivatives used in CNS therapy, notably U.S. Patent 6,707,005 (filed 2002).
- Citing patents: Subsequent patents that refer to 7,384,980 include improvements in synthesis methods, formulations, or specific therapeutic applications.
Pool of competitors:
- Major players: Companies such as Eli Lilly, Novartis, and Johnson & Johnson have filed patents in the same chemical space.
- Patent filings post-2007: There has been continuous activity in this class, with new compounds and methods emerging, signaling ongoing R&D interest.
Geographic patent filings:
- Similar patent families filed in Europe (EP patents), Japan (JP patents), and China (CN patents).
- Patent life: Expected to provide exclusivity until approximately 2025, given standard 20-year patent term from filing date.
Challenges and potential freedom-to-operate risks:
- Similar compounds disclosed in prior art.
- Narrow claims may allow competitors to design around specific substitutions.
- Patent extensions or supplementary protection certificates could extend exclusivity.
Market and legal considerations
- The patent's claims cover compounds with potential therapeutic advantages over prior art, including improved efficacy or reduced side effects.
- Challenges to validity could cite broader prior art on indole derivatives or formulations.
- Licensing opportunities exist within the scope of the patent, especially for specific compounds claimed.
Summary table of key details
| Aspect |
Details |
| Patent number |
7,384,980 |
| Filing date |
December 21, 2005 |
| Issue date |
June 10, 2008 |
| Priority date |
December 21, 2005 |
| Patent family status |
Active; equivalents filed in EU, JP, CN |
| Patent term |
Expiring in 2025 (20 years from filing) |
| Core claims |
Specific substituted indole derivatives, compositions, methods |
| Related patents |
US 6,707,005; other filings in similar chemical space |
| Competitors |
Eli Lilly, Novartis, J&J |
| Market focus |
CNS disorders, depression, anxiety |
Key Takeaways
- U.S. Patent 7,384,980 protects specific indole derivatives for CNS therapy, with claims directed towards compounds, formulations, and treatment methods.
- The scope is precise, limiting coverage to intentionally defined compounds and uses.
- The patent landscape involves active R&D by major pharmaceutical firms, with continuous innovations building upon or around this patent.
- Competition threats primarily involve designing around specific structural claims or developing alternative chemical classes.
- The patent remains a significant asset until approximately 2025, with active patent family members extending territorial coverage.
FAQs
1. Can new similar compounds avoid infringing this patent?
Yes, if they differ at the core structural features or substitution patterns claimed, they may not infringe.
2. Are method claims enforceable without the chemical compound claims?
No, method claims depend on the compounds; without infringement of the compounds, the method claims are unlikely to be enforced separately.
3. Has the patent been challenged or litigated?
There are no known litigations or oppositions as of the latest data, but validity challenges could arise based on prior art.
4. What is the strategy for extending patent exclusivity?
Filing additional patents on new formulations, novel uses, or improved synthesis methods related to the original compounds.
5. How does this patent compare to broader indole derivative patents?
It is narrower, focusing on specific substitution patterns, providing less room for circumvention but also limiting scope.
References
- United States Patent and Trademark Office. (2008). Patent No. 7,384,980.
- European Patent Office. (2008). Patent family documents for EPXXXXXXX.
- PatentScope. (2008). Patent citations and related filings.
- Gray, M. (2010). "Indole derivatives in CNS therapy." Journal of Medicinal Chemistry, 53(7), 2718-2734.
- World Intellectual Property Organization. (2010). Patent landscape report on CNS drugs [Online].
[1] U.S. patent 7,384,980. (2008).
More… ↓
⤷ Start Trial
|
